Conexeu Sciences Launches Preclinical Program for 3D-Printed Breast…

Event summary

Conexeu Sciences has initiated a preclinical development program for its B.R.E.A.S.T.™ bioregenerative matrix platform at the Wake Forest Institute for Regenerative Medicine.
The program will evaluate the durability, host tissue integration, and resorbability of the CXU™ 3D-printed B.R.E.A.S.T.™ matrix.
The technology is being developed as a potential alternative to permanent breast implants and traditional reconstruction approaches.
Conexeu is leveraging support from the RegenMed Development Organization (ReMDO) ecosystem for advanced bioprinting infrastructure.

The big picture

Conexeu Sciences' collaboration with the Wake Forest Institute for Regenerative Medicine underscores the growing trend of biotechnology companies leveraging advanced bioprinting infrastructure to develop next-generation regenerative therapies. The strategic partnership aims to de-risk innovation and accelerate the translation of the B.R.E.A.S.T.™ platform toward clinical impact, potentially disrupting the traditional breast implant market. The company's focus on bioregenerative approaches represents a significant evolution beyond conventional implant technologies, aligning with broader industry shifts toward more natural, patient-specific solutions.

What we're watching

Clinical Translation: The pace at which preclinical findings will inform the design of future studies and guide progression toward clinical development.
Regulatory Strategy: Whether Conexeu can sustain its predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027.
Market Expansion: How Conexeu's progress on 3D printing will affect its expansion into new indications and markets, including veterinary applications.